Literature DB >> 20031859

Medication underuse during long-term follow-up in patients with peripheral arterial disease.

Sanne E Hoeks1, Wilma J M Scholte op Reimer, Yvette R B M van Gestel, Olaf Schouten, Mattie J Lenzen, Willem-Jan Flu, Jan-Peter van Kuijk, Corine Latour, Jeroen J Bax, Hero van Urk, Don Poldermans.   

Abstract

BACKGROUND: Patients with peripheral arterial disease constitute a high-risk population. Guideline-recommended medical therapy use is therefore of utmost importance. The aims of our study were to establish the patterns of guideline-recommended medication use in patients with PAD at the time of vascular surgery and after 3 years of follow up, and to evaluate the effect of these therapies on long-term mortality in this patient group. METHODS AND
RESULTS: Data on 711 consecutive patients with peripheral arterial disease undergoing vascular surgery were collected from 11 hospitals in the Netherlands (enrollment between May and December 2004). After 3.1+/-0.1 years of follow-up, information on medication use was obtained by a questionnaire (n=465; 84% response rate among survivors). Guideline-recommended medical therapy use for the combination of aspirin and statins in all patients and beta-blockers in patients with ischemic heart disease was 41% in the perioperative period. The use of perioperative evidence-based medication was associated with a reduction of 3-year mortality after adjustment for clinical characteristics (hazard ratio, 0.65; 95% CI, 0.45 to 0.94). After 3 years of follow-up, aspirin was used in 74%, statins in 69%, and beta-blockers in 54% of the patients respectively. Guideline-recommended medical therapy use for the combination of aspirin, statins, and beta-blockers was 50%.
CONCLUSIONS: The use of guideline recommended therapies in the perioperative period was associated with reduction in long-term mortality in patients with peripheral arterial disease. However, the proportion of patients receiving these evidence-based treatments-both at baseline and 3 years after vascular surgery-was lower than expected based on the current guidelines. These data highlight a clear opportunity to improve the quality of care in this high-risk group of patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20031859     DOI: 10.1161/CIRCOUTCOMES.109.868505

Source DB:  PubMed          Journal:  Circ Cardiovasc Qual Outcomes        ISSN: 1941-7713


  12 in total

Review 1.  Exercise rehabilitation in peripheral artery disease: functional impact and mechanisms of benefits.

Authors:  Naomi M Hamburg; Gary J Balady
Journal:  Circulation       Date:  2011-01-04       Impact factor: 29.690

2.  Low-density lipoprotein lowering does not improve calf muscle perfusion, energetics, or exercise performance in peripheral arterial disease.

Authors:  Amy M West; Justin D Anderson; Frederick H Epstein; Craig H Meyer; Hongkun Wang; Klaus D Hagspiel; Stuart S Berr; Nancy L Harthun; Arthur L Weltman; Joseph M Dimaria; Jennifer R Hunter; John M Christopher; Christopher M Kramer
Journal:  J Am Coll Cardiol       Date:  2011-08-30       Impact factor: 24.094

3.  Outcomes Among hypertensive patients with concomitant peripheral and coronary artery disease: findings from the INternational VErapamil-SR/Trandolapril STudy.

Authors:  Anthony A Bavry; R David Anderson; Yan Gong; Scott J Denardo; Rhonda M Cooper-Dehoff; Eileen M Handberg; Carl J Pepine
Journal:  Hypertension       Date:  2009-12-07       Impact factor: 10.190

4.  Secondary prevention and mortality in peripheral artery disease: National Health and Nutrition Examination Study, 1999 to 2004.

Authors:  Reena L Pande; Todd S Perlstein; Joshua A Beckman; Mark A Creager
Journal:  Circulation       Date:  2011-06-20       Impact factor: 29.690

Review 5.  Sex Differences in Peripheral Artery Disease.

Authors:  Maria Pabon; Susan Cheng; S Elissa Altin; Sanjum S Sethi; Michael D Nelson; Kerrie L Moreau; Naomi Hamburg; Connie N Hess
Journal:  Circ Res       Date:  2022-02-17       Impact factor: 23.213

6.  Association of Statin Dose With Amputation and Survival in Patients With Peripheral Artery Disease.

Authors:  Shipra Arya; Anjali Khakharia; Zachary O Binney; Randall R DeMartino; Luke P Brewster; Philip P Goodney; Peter W F Wilson
Journal:  Circulation       Date:  2018-01-12       Impact factor: 29.690

7.  Patient and physician related factors of adherence to evidence based guidelines in diabetes mellitus type 2, cardiovascular disease and prevention: a cross sectional study.

Authors:  Johanna Fürthauer; Maria Flamm; Andreas Sönnichsen
Journal:  BMC Fam Pract       Date:  2013-04-04       Impact factor: 2.497

8.  Adherence to guideline-recommended therapies among patients with diverse manifestations of vascular disease.

Authors:  Debbie C Chen; Ehrin J Armstrong; Gagan D Singh; Ezra A Amsterdam; John R Laird
Journal:  Vasc Health Risk Manag       Date:  2015-03-03

9.  Adherence to guideline-recommended therapy is associated with decreased major adverse cardiovascular events and major adverse limb events among patients with peripheral arterial disease.

Authors:  Ehrin J Armstrong; Debbie C Chen; Gregory G Westin; Satinder Singh; Caroline E McCoach; Heejung Bang; Khung-Keong Yeo; David Anderson; Ezra A Amsterdam; John R Laird
Journal:  J Am Heart Assoc       Date:  2014-04-10       Impact factor: 5.501

10.  Race and Socioeconomic Status Independently Affect Risk of Major Amputation in Peripheral Artery Disease.

Authors:  Shipra Arya; Zachary Binney; Anjali Khakharia; Luke P Brewster; Phil Goodney; Rachel Patzer; Jason Hockenberry; Peter W F Wilson
Journal:  J Am Heart Assoc       Date:  2018-01-12       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.